|Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021|
|By: PR Newswire Association LLC. - 12 May 2021||Back to overview list
NEWARK, Calif., May 12, 2021 /PRNewswire/ -- Protagonist Therapeutics ("Protagonist" or the "Company") (Nasdaq: PTGX), today announced that an abstract highlighting updated data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera ("PV") has been selected for an oral presentation at the upcoming European Hematology Association ("EHA") 2021 Annual Congress. The EHA Congress will take place virtually June 9-17, 2021. Rusfertide, a synthetic, injectable hepcidin mimetic, regulates iron homeostasis and controls the absorption, storage, and distribution of iron in the body. Rusfertide was discovered through the Company's peptide technology platform.
"We are delighted that our abstract has been selected for an oral presentation at the EHA Congress," said Sam Saks, M.D., Chief Medical Officer at Protagonist. "This is an internationally recognized event with broad attention from the worldwide hematology community. We look forward to expanding upon our previously reported Phase 2 data in eighteen patients at the American Society of Hematology meeting, which demonstrated almost complete elimination of phlebotomy treatment; reversal of iron deficiency; a decrease of symptom burden; and maintenance of hematocrit levels below 45 percent, per guidelines set by the National Comprehensive Cancer Network. We have recently announced completion of the targeted enrollment of fifty patients in this ongoing study."
Oral Presentation Details
Title: Rusfertide (PTG-300) Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera (PV) Patients
The abstract can be accessed online on the EHA 2021 meeting library website, ehaweb.org. All presentations will be available on demand to registered meeting attendees on the EHA virtual Congress platform as of June 11, 2021.
About Polycythemia Vera
About Protagonist Therapeutics
PN-943 is an investigational orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates, PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms. Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-presentation-of-updated-results-from-phase-2-study-of-rusfertide-in-polycythemia-vera-selected-for-oral-presentation-at-eha-2021-301289981.html
SOURCE Protagonist Therapeutics, Inc.
Copyright 2021 PR Newswire Association LLC.
|Back to overview list|